Skip to main content

Tasigna (nilotinib) Disease Interactions

There are 8 disease interactions with Tasigna (nilotinib):

Major

Nilotinib (applies to Tasigna) pancreatitis

Major Potential Hazard, Moderate plausibility.

Nilotinib can cause increases in serum lipase. Patients with a previous history of pancreatitis might be at increased risk and should be monitored carefully for lipase elevations and any abdominal symptoms. Serum lipase should be monitored monthly or as clinically indicated and treatment might need to be interrupted until pancreatitis is excluded as a diagnosis.

Major

Nilotinib (applies to Tasigna) QT prolongation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Hypokalemia, Magnesium Imbalance

Nilotinib should not be used in patients with hypokalemia, hypomagnesemia or long QT syndrome, as it has shown to prolong QT interval in a concentration-dependent manner. This can cause a ventricular tachycardia called Torsade de Pointes which can result in syncope, seizures, and/or death. Before initiating nilotinib, electrolytes should be tested. Hypokalemia or hypomagnesemia should be corrected before starting treatment and monitored periodically. Patients at risk should be monitored with an EKG before and during treatment as clinically indicated and dose adjustments might be needed.

Moderate

BCR-ABL tyrosine kinase inhibitors (applies to Tasigna) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility.

Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors. If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention. The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.

Moderate

BCR-ABL tyrosine kinase inhibitors (applies to Tasigna) fluid retention

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Pleural Effusion

Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure. Monitor and manage patients using standards of care. Interrupt, reduce dose or discontinue therapy as necessary.

Moderate

BCR-ABL tyrosine kinase inhibitors- bone marrow suppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors. Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression. A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated. To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.

Moderate

Nilotinib (applies to Tasigna) electrolyte abnormalities

Moderate Potential Hazard, Moderate plausibility.

Nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities should be corrected prior to initiating nilotinib and during therapy, and should be monitored periodically.

Moderate

Nilotinib (applies to Tasigna) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Nilotinib exposure is increased in patients with hepatic impairment. The use of a lower starting dose might be needed. Additionally, there have been reports of hepatotoxicity as measured by elevations in bilirubin, AST, ALT and alkaline phosphatase. Liver function should be monitored before initiation of treatment and regularly during therapy. Dose reduction or interruption might be needed if laboratory abnormalities are found.

Moderate

Nilotinib (applies to Tasigna) lactose intolerance

Moderate Potential Hazard, Moderate plausibility.

Nilotinib capsules contain lactose, so it is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose- containing products, or of glucose-galactose malabsorption.

Tasigna (nilotinib) drug interactions

There are 686 drug interactions with Tasigna (nilotinib)

Tasigna (nilotinib) alcohol/food interactions

There is 1 alcohol/food interaction with Tasigna (nilotinib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.